EBS

5.0501.94%
DW

Donald W. DeGolyer

Independent Director

Mr. Donald W. DeGolyer, also known as Don, is Director of Subject Well, Inc. from June 2025. He serves as Independent Director at Emergent BioSolutions Inc. since October 1, 2023. He serves as Director of Xevant, Inc. from July 2023. Previously, he served as a Senior Healthcare Advisor at Koch Investment, where he developed a tech-enabled growth equity investment strategy. Currently, he is advising TrialSpark. He served as Chief Executive Officer of Vertice Pharma, LLC and served as its President. Mr. DeGolyer had been Director at Vertice Pharma, LLC since September 2020 until 2022. He serves as Executive Director of Vertice Pharma UK Parent Ltd. He served as a Special Advisor to the Chief Executive Officer at Endo International plc (formerly, Endo Health Solutions Inc) from March 2015 to August 1, 2015. Mr. DeGolyer served as the Chief Operating Officer, Pharmaceuticals/Chief Operating Officer at Endo Pharmaceuticals Inc. from 2013 to 2015. Mr. DeGolyer served as the Chief Operating Officer of Pharmaceuticals at Endo International plc (formerly Endo Health Solutions Inc) from August 1, 2013 to March 1, 2015. He served as Head of North America at Sandoz International GmbH since April 2010. He served as the Head of Commercial Operations - North America of Sandoz, Inc., Novartis’ North America generic pharmaceuticals unit. He served as President and CEO of Sandoz North America from 2010 to 2013. He joined Sandoz in October 2009 as Senior Vice President and Head of US Commercial Operations. In this role, he was responsible for the retail, institutional & the biologic operating units and oversaw the US product portfolio & product management activities. He served as Senior Vice President, U.S. Managed Markets and Established Medicines at Novartis Pharmaceuticals Corporation and Vice President of U.S. Managed Markets since November 2002. Mr. DeGolyer has responsibility for leading the multiple functions that comprise the U.S. Managed Markets organization, which include large account sales and marketing, including PBMs, Health Plans, Medicare, Medicaid, VA, DoD, Senior Care, Retail Pharmacies, Wholesalers, Larger Employers and Customer Marketing. Prior to joining Novartis, he served as the President of Global Therapeutics at Oxford GlycoSciences Plc, a world leader in proteomics and rare diseases. He served as Vice President of Marketing and Sales at Pfizer Inc. He served as Vice President of U S Managed Markets at Novartis Pharmaceuticals Corporation since November 2002. Mr. DeGolyer founded Vertice Pharma in 2015. Mr. DeGolyer has experience in the pharmaceuticals industry, beginning at Pfizer Inc. in Sales and Sales Management. He spent many years at Johnson & Johnson in various roles of increasing responsibility, including Vice President of Marketing & Sales. He is a uniquely qualified, seasoned leader experience in the healthcare industry. He has broad experience in both branded and generic pharmaceuticals. He then moved to Parkstone Medical, an innovator in point of care technology, where he served as Chief Operating Officer and Executive Vice President. He had been a Director of Tyme Technologies, Inc. since May 24, 2018 until September 16, 2022. He was an Independent Director of HLS Therapeutics Inc. from March 12, 2018 to June 16, 2023. He served as Vice Chairman of Association for Accessible Medicines (a/ka/ Generic Pharmaceutical Association) since February 2012. Mr. DeGolyer received an MBA in Marketing from Fairleigh Dickinson University and a Bachelor of Arts degree in Political Science from University of Rochester.

Positions